/
CLRB
$2.60+$0.08 (+3.17%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$20.1M
8M shares
52-week range
$2.20 – $8.05
7% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
70.38%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-348.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $82.3K | $189.4K | $0 | $0 | $0 | $0 | $0 | $213.6K |
| Gross profit | −$82.3K | −$189.4K | $0 | $0 | $0 | $0 | $0 | −$213.6K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.8M | $9.0M | $10.1M | $17.6M | $19.2M | $27.3M | $26.1M | $11.5M |
| Operating income | −$13.3M | −$14.2M | −$15.3M | −$24.1M | −$28.8M | −$39.0M | −$51.8M | −$23.0M |
| EBITDA | −$13.2M | −$13.9M | −$14.9M | −$24.0M | −$31.7M | −$42.6M | −$44.2M | −$21.6M |
| Net income | −$13.2M | −$14.1M | −$15.1M | −$24.1M | −$31.8M | −$42.8M | −$44.6M | −$21.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1567.96 | -550.86 | -228.55 | -130.35 | -135.18 | -104.99 | -41.89 | -8.35 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-2.05 | $-2.49–$-1.59 | 2 |
| 2027 | $7M | $-1.60 | $-2.12–$-1.08 | 2 |
| 2028 | $46M | $-0.34 | $-0.37–$-0.30 | 2 |
| 2029 | $99M | $0.77 | $0.77–$0.77 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.38
Price
$2.60
Implied upside
+69%
Peer comparison
Cellectar Biosciences INC NEW
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
www.cellectar.com- Employees
- 11
- IPO / List date
- Apr 19, 2005
- HQ
- FLORHAM PARK, NJ
Held by traders on TradeandTell
No one on the platform currently holds CLRB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 24,900 | $139.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-24 | 1-for-30reverse |
| 2022-07-22 | 1-for-10reverse |
| 2018-07-17 | 1-for-10reverse |
| 2016-03-07 | 1-for-10reverse |
| 2014-06-16 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded CLRB yet.
